Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D

NCT ID: NCT02492620

Last Updated: 2018-08-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-03-31
• Study Completion Date: 2017-11-30

Brief Summary

It is the investigators hypothesis that participants treated with Ferric Citrate (FC) during the non-dialysis CKD stage (4/5) with sufficient duration prior to initiating RRT, will result in improved biochemical control of anemia (Hb, TSAT) and mineral metabolism (P, FGF23) and furthermore, will result in a reduced need for ESA and intravenous iron. The investigators further hypothesize that effective treatment of anemia and mineral metabolism with FC in the pre-dialysis and transition period will result in improved physical functioning, reduced hospitalization and reduced total cost of care when compared to participants receiving contemporaneously provided standard of care therapy.

Detailed Description

This is an up to 50 week, phase 3, clinical trial in patients with estimated glomerular filtration rate (eGFR) ≤ 20 ml/min/1.73m2. It will be comprised of an up to 36-week non-dialysis period (NDP), or until such time as subjects require renal replacement therapy (RRT) with dialysis when they will immediately roll into a 12-week dialysis period (DP). The study will consist of up to 16 clinic visits over a maximum period of 50 weeks. There will be a screening period of up to 14 days after which subjects will be randomized into the NDP in a 2:1 ratio to receive either FC (n=150) or SOC (n=75). Each eligible participant will be randomized to either fixed dose open-label ferric citrate (FC) or standard of care (SOC) treatment. Participants randomized to SOC will receive care directed by their primary nephrologist throughout the study duration with the only restriction being that they cannot receive treatment with FC during the NDP or DP. Participants randomized to FC will receive it throughout the study duration.

220 participants were screened to randomize 200 subjects 2:1 (FC:SOC) into the NDP. It is anticipated that 35-45% of participants will reach the dialysis period (DP) during the 36 week follow up. Participants who initiate RRT with dialysis will enter the Dialysis Period (DP) during which those participants previously assigned to ferric citrate will continue to receive open-label ferric citrate and those previously assigned to SOC will receive open-label, non-FC phosphate binders at the discretion of their treating physician. During this period all participants will be treated to standard of care guidelines which suggest that if serum phosphate is above the upper limit of normal (4.5 mg/dL), it should be reduced. During the DP, dose of P binders, use of ESA, intravenous iron and blood transfusions will be at the discretion of the primary treating nephrologist. Participants assigned to the SOC treatment arm may not receive FC at any point during the study.

Only participants that begin permanent RRT with dialysis will be eligible to enter the 12 week DP. Participants that do not begin RRT after 9 months participation in the NDP will be deemed to have reach the end of study and have end of study procedures performed.

Conditions

Chronic Kidney Disease; Hyperphosphatemia; Iron Deficiency Anemia; Renal Insufficiency

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ferric Citrate

Ferric citrate (FC) will be supplied as tablets containing 210mg of ferric iron (as 1g ferric citrate) to those subjects randomized to FC. These participants will be initiated on study drug with a fixed dose of FC beginning with 2 tablet per meal.

Group Type: ACTIVE_COMPARATOR

Ferric Citrate

Intervention Type: DRUG

Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis

Standard of Care (SOC)

Participants may receive open-label, non-FC phosphate binders at the discretion of their treating physician. During the Dialysis Period, dose of phosphate binders, use of ESA, intravenous iron and blood transfusions will be at the discretion of the primary treating nephrologist. Participants assigned to the SOC treatment arm may not receive FC at any point during the study.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Ferric Citrate

Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis

Intervention Type: DRUG

Other Intervention Names

Auryxia

Eligibility Criteria

Inclusion Criteria

1. Age >18 years at screening visit

2. Serum phosphate > or equal to 3.0 mg/dL obtained at screening

3. CKD with eGFR < or equal to 20 mL/min obtained at screening*

4. Hemoglobin (Hgb) >8.0 g/dL obtained at screening

5. TSAT <55% obtained at screening

6. Females of child bearing potential with negative serum pregnancy test obtained at screening

7. Willing and able to give written informed consent

8. Anticipated to have > or equal to 8 weeks prior to need for initiating RRT in the opinion of the investigator

Exclusion Criteria

1. Liver enzymes (ALT/AST) >X3 times upper limit of normal at screening

2. Use of IV iron, blood transfusions or ESA agents within 2 weeks prior to the screening visit and prior to the Day 1 visit.

3. Evidence of acute kidney injury (i.e., no CKD) or planned need for RRT within 12 weeks of screening

4. Scheduled kidney transplant within 24 weeks of screening

5. Contra-indication to ferric citrate: iron overload syndrome, allergic reaction or known intolerance to ferric citrate

6. Clinically significant medical condition felt to interfere with tolerance of oral medication

7. Life expectancy < 6 months or confirmed conviction that subject does NOT want to initiate RRT despite a decline in kidney function

8. Active drug or alcohol dependence or abuse (excluding tobacco use or marijuana use) within the 12 months prior to screening (in the opinion of the PI)

9. Psychiatric disorder that interferes with the subject's ability to comply with the study protocol in the opinion of the PI

10. Any other medical condition that, in the opinion of the PI, renders the subject unable to or unlikely to complete the trial or that would interfere with optimal participation in the trial or produce significant risk to the subject

11. Inability to cooperate with study personnel or study procedures

12. Females who are pregnant or breastfeeding

13. Receiving or has received any investigational drug with in the past 30 days prior to the Day 1 visit

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Keryx Biopharmaceuticals

INDUSTRY

Sponsor Role: collaborator

Denver Nephrologists, P.C.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Geoffrey A Block, MD

Role: PRINCIPAL_INVESTIGATOR

Denver Nephrologists, P.C.

Locations

Denver Nephrologists, P.C.

Denver, Colorado, United States

Countries

United States

References

Natale P, Green SC, Ruospo M, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.

Reference Type: DERIVED

PMID: 40576086 (View on PubMed)

Other Identifiers

05D

Identifier Type: -

Identifier Source: org_study_id